Identification of SLIT3 mutation as a response biomarker for immune checkpoint inhibitor therapy in non-small cell lung cancer.
Saved in:
| Title: | Identification of SLIT3 mutation as a response biomarker for immune checkpoint inhibitor therapy in non-small cell lung cancer. |
|---|---|
| Authors: | Wang W; Department of Clinical Laboratory, Beilun People's Hospital, Ningbo, P. R. China., Wang J; Department of Clinical Laboratory, Beilun People's Hospital, Ningbo, P. R. China., Ge T; Department of Clinical Laboratory, Beilun People's Hospital, Ningbo, P. R. China., Wang X; Precision Medicine Research Centre, Beilun People's Hospital, Ningbo, P. R. China., Yang M; Department of Gynecology, Huzhou Maternity & Child Health Care Hospital, Huzhou, China., Zhu J; Precision Medicine Research Centre, Beilun People's Hospital, Ningbo, P. R. China., Ji C; Department of Clinical Laboratory, Beilun People's Hospital, Ningbo, P. R. China. blrmyychaoge369@163.com., Shu P; Precision Medicine Research Centre, Beilun People's Hospital, Ningbo, P. R. China. 17757498873@163.com. |
| Source: | Discover oncology [Discov Oncol] 2026 Mar 23; Vol. 17 (1). Date of Electronic Publication: 2026 Mar 23. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 101775142 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-6011 (Electronic) Linking ISSN: 27306011 NLM ISO Abbreviation: Discov Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
